Exelixis, Inc. (EXEL) announced that the District Court of Delaware has ruled in its favor in the second patent litigation against MSN Laboratories. MSN is seeking approval for its generic product of Exelixis' cabozantinib. Details of EXEL's Patent Litigation Cabozantinib is marketed under the brand name Cabometyx for the treatment of renal cell carcinoma (RCC). EXEL has been involved in a lawsuit with MSN since 2019, when the latter submitted an abbreviated new drug application (ANDA) to the FDA requesting ...

Exelixis, Inc. (EXEL) entered into a clinical development collaboration agreement with pharma giant Merck (MRK) to advance the development of its pipeline candidate, zanzalintinib. Zanzalintinib, an investigational tyrosine kinase inhibitor (TKI), inhibits multiple cancer-related pathways that play a key role in resistance to multiple therapies, including immune checkpoint inhibitors. Shares of Exelixis have risen 9.4% year to date compared with the industry's growth of 6.3%. Image Source: Zacks Investment ...

Shares of Exelixis, Inc. (EXEL) have risen 20.7% in the past three months compared with the industry's growth of 6.3%. The stock has also outperformed the sector and the S&P 500 Index. Exelixis has been a consistent outperformer in the year so far on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress. EXEL Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Cabometyx Boosts EXEL Cabometyx maintained its status as the leading tyrosine ki ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revisi ...

No need to break the bank to get in on these likely long-term winners. Stocks with solid growth prospects aren't always trading for exorbitant sticker prices. Whether they recently conducted a stock split, their shares dropped unjustifiably, or the market isn't seeing their potential, there are many reasons why otherwise attractive companies would trade for less than $100 despite being on the market for a while. Companies in this category can allow people to invest on a budget, at least for those who prefer ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, whil ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

In a market dealing with external shocks, value investing is fast gaining popularity. The success of value investors like Warren Buffett underscores this. Buffett and his business partner, Charlie Munger, managed to register more than 19.8% CAGR for Berkshire Hathaway from 1965 through 2023. This compares favorably with a 10.2% rise of the S&P 500 Index during the same period. In this article, we discuss how the price/earnings to growth (PEG) ratio can become an efficient yardstick in picking the best value ...